We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current SYRE market cap is 884.24M. The company's latest EPS is USD -3.4511 and P/E is -4.24.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -47.75M | -47.77M | -44.15M | -55.39M | -61.25M |
| Net Income | -63.13M | -43.86M | -38.84M | -69.03M | -56.3M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 18.74M | 2.33M | 886k | 0 |
| Operating Income | -81.48M | -65.65M | -84.78M | -258.75M | -208.57M |
| Net Income | -80.89M | -65.8M | -83.82M | -338.79M | -208.02M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 341.86M | 487.6M | 436.07M | 421.09M | 608.48M |
| Total Liabilities | 73.29M | 81.93M | 61.68M | 93.7M | 90.68M |
| Total Equity | 184.02M | 152.27M | 374.39M | 327.39M | 517.8M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 161.62M | 109.93M | 71.14M | 341.86M | 608.48M |
| Total Liabilities | 21.79M | 25.99M | 20.84M | 73.29M | 90.68M |
| Total Equity | 139.83M | 83.94M | 50.31M | 184.02M | 517.8M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -99.91M | -28.54M | -90.79M | -120.21M | -157.41M |
| Investing | -108.39M | -104.96M | -225.48M | -182.74M | -353.29M |
| Financing | 361.08M | 172.17M | 172.53M | 185.31M | 410.91M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -75.78M | -53.72M | -80.14M | -99.91M | -157.41M |
| Investing | -7.6M | -22.62M | 57.01M | -108.39M | -353.29M |
| Financing | 154.51M | 1.39M | 42.68M | 361.08M | 410.91M |
| Market Cap | 884.24M |
| Price to Earnings Ratio | -4.24 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 9.85 |
| Price to Book Ratio | 1.7 |
| Dividend Yield | - |
| Shares Outstanding | 60.28M |
| Average Volume (1 week) | 649.18k |
| Average Volume (1 Month) | 878.35k |
| 52 Week Change | -56.89% |
| 52 Week High | 40.49 |
| 52 Week Low | 10.91 |
| Spread (Intraday) | 11 (52.38%) |
| Company Name | Spyre Therapeutics Inc |
| Address |
1521 concord pike wilmington, delaware 19803 |
| Website | https://www.spyre.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
